Abstract 739P
Background
Penile squamous cell carcinoma (PSCC) is rare and the immune enviroment of PSCC remains poorly characterized. In this study, we characterize the immune microenvironment using multiplex immunofluorescence (mIF) and image analysis approaches in 57 patients with PSCC.
Methods
Representative tissue microarrays blocks of 57 patients with primary PSCC treated at H. Lee Moffitt Cancer Center (Tampa, FL) were stained for 10 immune markers: CD20, CD3, CD4, CD8, CD45RO, CD68, CD206, CD163, NKp46, FOXP3. Two experienced pathologists using an image analysis system divided each tissue core into tumor and stroma compartments and assessed the densities of cell phenotypes.For analyses focusing on overall survival (OS) we used Cox regression and Log-rank test for Kaplan-Meier plots. The maximally selected rank statistics test was used to identify cut-points of continuous variables with maximal discriminatory value for clinical outcomes.
Results
57 PSCC patients were included with median age 60 [IQR, 53-73]). 25 (44%) were pathologic stages 1-2, 25 (44%) were stage 3, and 7 (12%) were stage 4. 34 (60%) were HPV-negative. We did not observe significant differences in cell densities as defined by mIF in HPV(+) compared to HPV(–) PSCC. In univariable analysis, higher density of CD8+ cells in the tumor and stroma were associated with inferior median OS (36.6 months [95% CI, 19.0-84.1] vs 161.7 months [95% CI, 16.2-161.7]). Similarly, greater infiltration by tumor-associated (M2) macrophages in the tumor and stroma (CD68+CD163+CD206+) were associated with inferior median OS (13.3 months [95% CI, 1.0-not estimable) vs 80.1 months [95% CI, 27.1-161.2]. In Cox regression controlling for pathologic stage and M2 density as a continuous variable, the latter remained significantly associated with OS.
Conclusions
Multiplex image analysis of primary PSCC found no difference in the immune contexture of HPV(+) and HPV(-) patients. High levels of tumor-associated macrophages M2 was associated with inferior survival outcomes. Further characterization of T-cell subsets to gauge the exhausted status of T-cells is underway to explain the paradoxical effect noted, similar to that in kidney cancer immune environment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. Chahoud.
Funding
Has not received any funding.
Disclosure
S. Eschrich: Financial Interests, Personal, Member of Board of Directors: Cvergenx. P. Spiess: Non-Financial Interests, Institutional, Trial Chair: NCCN; Non-Financial Interests, Institutional, Speaker, Consultant, Advisor: ASCO/EAU; Non-Financial Interests, Personal and Institutional, Ownership Interest: Global Society of Rare GU Tumors. All other authors have declared no conflicts of interest.
Resources from the same session
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18